PRS-300 series B and C

N/A

Report date: 2025/03/20 14:52:08

Base Information

Drug NamePRS-300 series B and C
Drug Alias Name300 series B and C anticalin-antibody fusion proteins (Pieris Pharmaceuticals)300 series-B anticalins (Pieris)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionImmunomodulators
TargetsUpdating
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPieris Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesPieris Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A